+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Pegfilgrastim"

Filgrastim Biosimilars Global Market Report 2024 - Product Thumbnail Image

Filgrastim Biosimilars Global Market Report 2024

  • Report
  • February 2024
  • 250 Pages
  • Global
From
Pegfilgrastim Biosimilars Global Market Report 2024 - Product Thumbnail Image

Pegfilgrastim Biosimilars Global Market Report 2024

  • Report
  • February 2024
  • 250 Pages
  • Global
From
From
Filgrastim - Biosimilar Insight, 2022 - Product Thumbnail Image

Filgrastim - Biosimilar Insight, 2022

  • Report
  • January 2022
  • 70 Pages
  • Global
From
From
Pegfilgrastim- Biosimilar Insight, 2022 - Product Thumbnail Image

Pegfilgrastim- Biosimilar Insight, 2022

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
  • 12 Results (Page 1 of 1)
Loading Indicator

Pegfilgrastim is a type of oncology drug used to treat neutropenia, a condition in which the body does not produce enough white blood cells. It is a long-acting form of filgrastim, a recombinant human granulocyte colony-stimulating factor (G-CSF) that stimulates the production of neutrophils, a type of white blood cell. Pegfilgrastim is used to reduce the duration and severity of neutropenia and the associated risk of infection in patients receiving chemotherapy for certain types of cancer. It is also used to reduce the duration of neutropenia and the associated risk of infection in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs. Pegfilgrastim is available in both brand-name and generic forms. It is marketed by several pharmaceutical companies, including Amgen, Teva Pharmaceuticals, Mylan, and Sandoz. Show Less Read more